{
    "clinical_study": {
        "@rank": "46", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Determine whether physiologic testosterone replacement can increase\n      fat-free mass, therefore contributing to weight maintenance, improved muscle function, and\n      quality of life in HIV-infected women.\n\n      II.  Examine the mechanism of testosterone-induced increase in fat-free mass."
        }, 
        "brief_title": "Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women", 
        "condition": [
            "HIV Infections", 
            "Cachexia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cachexia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study.  Patients\n      are randomized to one of three arms.\n\n      Arm I:  Patients receive two placebo transdermal patches applied twice a week (every 3-4\n      days).\n\n      Arm II:  Patients receive one testosterone transdermal patch and one placebo transdermal\n      patch applied twice a week (every 3-4 days).\n\n      Arm III:  Patients receive two testosterone transdermal patches applied twice a week (every\n      3-4 days).\n\n      Patients receive 12 weeks of treatment in the absence of adverse reaction or health\n      deterioration.  Patients are followed on day 1, every 2 weeks during treatment, and at the\n      end of the recovery period.  Quality of life is assessed before treatment begins and at\n      weeks 6 and 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Histologically confirmed premenopausal HIV-positive women who have experienced 5-15%\n             weight loss\n\n        --Prior/Concurrent Therapy--\n\n          -  Endocrine therapy: At least 3 months since megestrol At least 3 months since anabolic\n             or androgenic steroids At least 3 months since oral contraceptives At least 3 months\n             since Depo-Provera No concurrent hormone replacement therapy\n\n          -  Other: Concurrent retroviral or protease inhibitors allowed, dosage must be stable At\n             least 3 months since ketoconazole At least 6 weeks since the initiation of protease\n             inhibitors\n\n        --Patient Characteristics--\n\n          -  Hepatic: No significant liver disease SGOT/SGPT no greater than 3 times upper limit\n             of normal (ULN) Alkaline phosphatase no greater than 3 times ULN Bilirubin no greater\n             than 2 mg/dL No medical complications due to alcohol abuse\n\n          -  Renal: Not specified\n\n          -  Cardiovascular: No significant cardiovascular disease No uncontrolled hypertension\n\n          -  Other: Testosterone level (early morning) less than 30 ng/dL Normal gastrointestinal\n             function as indicated by: Absence of diarrhea Normal D-xylose absorption test No\n             acute opportunistic infections or infectious illness No malignant disease No history\n             of breast cancer No history of endometrial cancer No fever of known or unknown origin\n             No unremitting diarrhea defined as: At least 4 watery stools per day OR More than 4\n             watery stools recently OR Acute change in stool habit with fever No significant\n             respiratory disease No diabetes No illicit drugs within the past 6 months No history\n             of hyperandrogenic disorders such as: Hirsutism Polycystic ovary disease Not pregnant\n             or lactating"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "56", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004400", 
            "org_study_id": "199/13251", 
            "secondary_id": "CDUMS-FDR001397"
        }, 
        "intervention": {
            "intervention_name": "testosterone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "keyword": [
            "cachexia", 
            "disease-related problem/condition", 
            "human immunodeficiency virus infection", 
            "immunologic disorders and infectious disorders", 
            "nutrition", 
            "quality of life", 
            "rare disease", 
            "viral infection"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "contact": {
                    "last_name": "Shalender Bhasin", 
                    "phone": "213-563-9353"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90059"
                    }, 
                    "name": "Charles R. Drew University of Medicine and Science"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "G. Beall", 
                    "phone": "310-222-2444"
                }, 
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90509"
                    }, 
                    "name": "Los Angeles County Harbor-UCLA Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "K. Yarashaski", 
                    "phone": "314-362-9700"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Charles Drew University of Medicine and Science", 
            "last_name": "Shalender Bhasin", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004400"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Charles Drew University of Medicine and Science", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "April 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1998"
    }, 
    "geocoordinates": {
        "Charles R. Drew University of Medicine and Science": "34.052 -118.244", 
        "Los Angeles County Harbor-UCLA Medical Center": "33.836 -118.341", 
        "Washington University School of Medicine": "38.627 -90.199"
    }
}